– USA, NY – Royalty Pharma plc (Nasdaq: RPRX) announced the appointments of Dr. Carole Ho (MD) and Bess Weatherman to its Board of Directors, effective immediately.
About Dr. Carole Ho
Carole Ho has 20 years of experience in biopharma. She currently serves as CMO and Head of Development at Denali Therapeutics, where she heads therapeutic development from early-stage planning to late-stage development in rare disease and neurology. Since 2018, she has also served on non-profit, private, and public boards. Before Denali, she was VP of Clinical Development at Genentech, where she led development of therapeutics in neurology, immunology, ophthalmology, and infectious disease.
Carole Ho received an SB in biochemistry, magna cum laude, from Harvard University and earned her MD, with honors in research, from Weill Cornell Medicine.
About Elizabeth Weatherman
Bess Weatherman is a seasoned investor of 35 years across the healthcare industry. She serves as a Special Limited Partner at Warburg Pincus, which she joined in 1988. During her tenure, she held the role of Partner, was a member of the Executive Management Group, and led the firm’s Healthcare Group. She has served on the boards of numerous public and private companies and brings a deep understanding of capital markets, corporate governance, and medical innovation.
Bess Weatherman received a BA in English, summa cum laude and Phi Beta Kappa, from Mount Holyoke College and earned her MBA from the Stanford Graduate School of Business.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates.
For more: https://www.royaltypharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.